Annual report pursuant to Section 13 and 15(d)

Fair Value Measurement (Tables)

v2.4.1.9
Fair Value Measurement (Tables)
 12 Months Ended
Dec. 31, 2014
Fair Value Disclosures [Abstract]  
Financial instruments carried at fair value on a recurring
          Quoted Prices in Active Markets   Significant Other Observable Inputs   Unobservable Inputs  
Description   December 31, 2014     (Level 1)     (Level 2)     (Level 3)  
Assets:                        
Cash and cash equivalents   $ 3,970     $ 3,970     $ -     $ -  
Marketable securities     1,975       -       1,975       -  
Total assets   $ 5,945     $ 3,970     $ 1,975     $ -  
                                 
Liabilities:                                
Warrants potentially settleable in cash   $ 8,464     $ -     $ -     $ 8,464  
Total liabilities   $ 8,464     $ -     $ -     $ 8,464  
                                 
            Quoted Prices in Active Markets   Significant Other Observable Inputs   Unobservable Inputs  
Description   December 31, 2013     (Level 1)     (Level 2)     (Level 3)  
Assets:                                
Cash and cash equivalents   $ 1,034     $ 1,034     $ -     $ -  
Total assets   $ 1,034     $ 1,034     $ -     $ -  
                                 
Liabilities:                                
Derivative liability   $ 23     $ -     $ -     $ 23  
Total liabilities   $ 23     $ -     $ -     $ 23  
Level 3 financial assets and liabilities
    Fair Value Measurements Using Significant Unobservable Inputs (Level 3)  
    2014     2013  
Balance , January 1,   $ 23     $ 215  
Change in fair value of Teva option     (23)     (192)
Estimated fair value of warrants assumed in merger on January 2, 2014     10,475       -  
Estimated fair value of warrants issued in January common stock sale     3,696       -  
Change in fair value of warrants for the year ended December 31, 2014     (5,707)     -  
Balance at December 31,   $ 8,464     $ 23